AMPE (Ampio Pharmaceuticals) EV-to-EBIT: 0.37 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Ampio Pharmaceuticals EV-to-EBIT?

Ampio Pharmaceuticals AMPE -71.39% EV-to-EBIT is 0.37 as of Jul. 16, 2026.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ampio Pharmaceuticals's Enterprise Value is $-3.50 Mil. Ampio Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.52 Mil. Therefore, Ampio Pharmaceuticals's EV-to-EBIT for today is 0.37.

The historical rank and industry rank for Ampio Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

AMPE's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 13.95
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ampio Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $-2.11 Mil. Ampio Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.52 Mil. Ampio Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 451.66%.

Ampio Pharmaceuticals  (OTCPK:AMPE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Ampio Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-9.518/-2.10735
=451.66 %

Ampio Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $-2.11 Mil.
Ampio Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ampio Pharmaceuticals EV-to-EBIT Related Terms

Ampio Pharmaceuticals EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Ampio Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ampio Pharmaceuticals EV-to-EBIT Chart

Ampio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -74.41 -290.26 -92.88 0.42 0.22

Ampio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.35 0.21 0.31 0.22

AMPE vs EFTR, VBIVQ, VRTX: EV-to-EBIT Comparison

For the Biotechnology subindustry, Ampio Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ampio Pharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ampio Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ampio Pharmaceuticals's EV-to-EBIT falls into.


Ampio Pharmaceuticals EV-to-EBIT Calculation

Ampio Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-3.497/-9.518
=0.37

Ampio Pharmaceuticals's current Enterprise Value is $-3.50 Mil.
Ampio Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of 0.37 mean?
Ampio Pharmaceuticals (AMPE) has a EV-to-EBIT of 0.37 as of Jul. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ampio Pharmaceuticals and its competitors.
Is Ampio Pharmaceuticals' EV-to-EBIT too high?
Ampio Pharmaceuticals' current EV-to-EBIT is 0.37. The Biotechnology industry median EV-to-EBIT is 13.95. Ampio Pharmaceuticals' value of 0.37 is 97.3% below this industry median.
How does Ampio Pharmaceuticals' EV-to-EBIT compare to EFTR and VBIVQ?
Ampio Pharmaceuticals' EV-to-EBIT of 0.37 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 13.95. Ampio Pharmaceuticals' value of 0.37 is 97.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.95, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ampio Pharmaceuticals's current EV-to-EBIT of 0.37 is 97.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ampio Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ampio Pharmaceuticals's current EV-to-EBIT is 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ampio Pharmaceuticals stock overvalued right now?
Ampio Pharmaceuticals (AMPE) has a current EV-to-EBIT of 0.37. The current EV-to-EBIT is 0.37 and 97.3% below the Biotechnology industry median of 13.95. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ampio Pharmaceuticals (AMPE), the current EV-to-EBIT is 0.37 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ampio Pharmaceuticals Business Description

Address 9800 Mount Pyramid Court, Suite 400, Englewood, CO, USA, 80112
Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development of a potential treatment for osteoarthritis of the knee (OAK) as part of its OA-201 development program (OA-201 program or OA-201).